Posts by Peter W. PENG

Prostate cancer remains one of the most prevalent malignancies threatening men’s health worldwide. A major research focus today lies in developing accurate screening and diagnostic strategies that minimize the invasiveness and psychological burden of biopsy procedures. Landmark studies like SMART and PRECISION aim to address these challenges. At the 2025 European Association of Urology (EAU) Annual meeting, Professor Chiu Ka Fung Peter from the Department of Urology at The Chinese University of Hong Kong presented the latest findings from the SMART study. Following his presentation, Professor Chiu spoke with UroStream to share key updates in prostate cancer diagnostics and care.

Breast cancer remains one of the leading malignancies threatening women’s health worldwide. Among its various subtypes, hormone receptor-positive (HR⁺) breast cancer is the most prevalent, comprising about 70% of all cases. While the advent of CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) has become the gold standard for first-line treatment of HR⁺/HER2⁻ advanced breast cancer (MBC), therapeutic strategies following progression on CDK4/6i remain a considerable challenge. The introduction of the histone deacetylase inhibitor (HDACi) entinostat has brought a new horizon of hope for patients in this therapeutic gap. Recently, entinostat prescriptions were issued across major cities in China, such as Beijing and Guangdong, marking a pivotal moment in the treatment landscape. Oncology Frontier invited Dr. Xiaojia Wang from Zhejiang Cancer Hospital to delve deeper into the current status of HR⁺/HER2⁻ MBC treatment, strategies after CDK4/6i failure, and the efficacy and safety profile of entinostat.

Breast cancer remains one of the most prevalent malignancies among women worldwide, and its hormone receptor-positive, HER2-negative (HR+/HER2−) subtype accounts for nearly 70% of all cases. In recent years, the combination of CDK4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) has become the gold standard for first-line treatment in metastatic settings. However, once progression occurs on CDK4/6i-based regimens, the optimal path forward is less clearly defined, presenting a persistent challenge in clinical decision-making.

PARP inhibitors (PARPi) have ushered in a new era of precision treatment for prostate cancer. Multiple studies have confirmed that patients with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair deficiency mutations (HRRm) can benefit from this therapeutic approach. At the recently held 2025 European Association of Urology(EAU25) conference , a single-arm Phase II PROact study conducted by Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School，Nanjing University, was reported. The study demonstrated promising preliminary efficacy and safety of the combination of olaparib, abiraterone, and prednisone in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). UroStream was honored to invite Prof. Junlong Zhuang from Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School,Nanjing University, and Prof. Samson Chan from Department of Surgery, Tuen Mun Hospital, HONG KONG, to engage in a dialogue and share the latest advancements and clinical experiences in precision therapy for prostate cancer.

The emergence and evolution of natural orifice specimen extraction surgery (NOSES) in colorectal oncology marks a significant milestone in the journey toward scarless surgery. Since Professor Xishan Wang’s team first…

Editor's Note: The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded successfully. At this conference, two studies from Professor Xichun Hu’s team at Fudan University Shanghai Cancer Hospital…

Advanced urothelial carcinoma (UC) patients have a poor prognosis with a low 5-year survival rate. Since the 1980s, platinum-based chemotherapy has been the standard first-line therapy for locally advanced or metastatic UC (la/mUC), but the benefits are limited. The real-world tolerance and treatment outcomes of platinum therapy remain unclear. This year's study analyzed data from advanced UC patients in the United States. This article summarizes and organizes the findings for our readers.